or Try an Advanced Search...

    Antibody Drug Conjugate Stocks List

    Symbol Grade Name % Change
    GMAB F Genmab A/S 0.37
    ADCT F ADC Therapeutics SA -0.76
    CLDX D Celldex Therapeutics, Inc. -0.13
    KPTI D Karyopharm Therapeutics Inc. -0.81
    MRSN C Mersana Therapeutics, Inc. -9.68
    PYXS C Pyxis Oncology, Inc. -44.63
    ACLX C Arcellx, Inc. -0.09
    TGTX B TG Therapeutics, Inc. 11.52
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Long-Term Care Facilities
    Related Stock Lists: Cancer Medicine Biotechnology Clinical Medicine Monoclonal Antibodies Solid Tumors Immunology Monoclonal Antibody Treatment Of Cancer Acute Myeloid Leukemia Clinical Development Immunotherapies Lymphoma Biopharmaceutical Camidanlumab Tesirine Cancer Treatment Cd20 Chemotherapy Drugs Genetics

    Related ETFs - A few ETFs which own one or more of the above listed Antibody Drug Conjugate stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 6.09
    CANC D Tema Oncology ETF 4.78
    IDNA D iShares Genomics Immunology and Healthcare ETF 4.42
    SBIO C ALPS Medical Breakthroughs ETF 4.25
    PBE D PowerShares Dynamic Biotech & Genome 3.78
    View all Antibody Drug Conjugate ETFs...
    Compare ETFs
    Compare CANC to PBE Compare CNCR to IDNA Compare CNCR to PBE

        Antibody Drug Conjugate Stocks Recent News

        Date Stock Title
        Nov 21 PYXS Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
        Nov 21 PYXS Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade
        Nov 21 TGTX TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
        Nov 20 PYXS Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset
        Nov 20 PYXS Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
        Nov 20 KPTI Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
        Nov 20 CLDX Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
        Nov 20 CLDX Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
        Nov 18 KPTI Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition
        Nov 15 GMAB Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Long-Term Care Facilities
        Related Stock Lists: Cancer Medicine Biotechnology Clinical Medicine Monoclonal Antibodies Solid Tumors Immunology Monoclonal Antibody Treatment Of Cancer Acute Myeloid Leukemia Clinical Development Immunotherapies Lymphoma Biopharmaceutical Camidanlumab Tesirine Cancer Treatment Cd20 Chemotherapy Drugs Genetics
        Antibody Drug Conjugate

        An Antibody Drug Conjugate (ADC) is a type of targeted therapy used to treat cancer. It is a combination of an antibody, which is a protein that binds to a specific target on cancer cells, and a drug, which is a chemical that kills the cancer cells. The antibody is linked to the drug, allowing it to be delivered directly to the cancer cells. This targeted approach reduces the side effects of traditional chemotherapy, which can damage healthy cells as well as cancer cells.

        Browse All Tags